Compile Data Set for Download or QSAR
maximum 50k data
Found 168 with Last Name = 'bachmann' and Initial = 's'
TargetLysine-specific histone demethylase 1A(Homo sapiens (Human))TBA
LigandPNGBDBM50612500(CHEMBL5287761)
Affinity DataKi:  5.49E+3nMAssay Description:Inhibition of human recombinant LSD1 assessed as inhibition constant by HRP-coupled assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125036(US8772510, 55)
Affinity DataIC50:  0.390nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125038(US8772510, 57)
Affinity DataIC50:  0.470nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125040(Roche-Dataset for PDE10A, Compound 21 | US8772510,...)
Affinity DataIC50:  0.530nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125041(Roche-Dataset for PDE10A, Compound 0 | US8772510, ...)
Affinity DataIC50:  0.670nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125039(US8772510, 58)
Affinity DataIC50:  0.700nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125012(Roche-Dataset for PDE10A, Compound 130 | US8772510...)
Affinity DataIC50:  1.70nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125046(Roche-Dataset for PDE10A, Compound 22 | US8772510,...)
Affinity DataIC50:  1.83nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125013(Roche-Dataset for PDE10A, Compound 10 | US8772510,...)
Affinity DataIC50:  3.10nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125037(Roche-Dataset for PDE10A, Compound 78 | US8772510,...)
Affinity DataIC50:  3.41nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125026(Roche-Dataset for PDE10A, Compound 30 | US8772510,...)
Affinity DataIC50:  3.70nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125017(Roche-Dataset for PDE10A, Compound 267 | US8772510...)
Affinity DataIC50:  3.77nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124988(US8772510, 7)
Affinity DataIC50:  4nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125016(Roche-Dataset for PDE10A, Compound 32 | US8772510,...)
Affinity DataIC50:  5.66nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125043(Roche-Dataset for PDE10A, Compound 80 | US8772510,...)
Affinity DataIC50:  7.41nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMitochondrial 2-oxodicarboxylate carrier(Homo sapiens)
Michigan State University

Curated by ChEMBL
LigandPNGBDBM50240948(CHEMBL359965 | S-allyl prop-2-ene-1-sulfinothioate...)
Affinity DataIC50:  11nMAssay Description:Inhibition of ODC (unknown origin) expressed in Escherichia coli after 30 mins in presence of [1-14C] L-ornithine by liquid scintillation counter ana...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125008(Roche-Dataset for PDE10A, Compound 151 | US8772510...)
Affinity DataIC50:  11nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMitochondrial 2-oxodicarboxylate carrier(Homo sapiens)
Michigan State University

Curated by ChEMBL
LigandPNGBDBM50240948(CHEMBL359965 | S-allyl prop-2-ene-1-sulfinothioate...)
Affinity DataIC50:  11nMAssay Description:Inhibition of ODC (unknown origin) expressed in Escherichia coli after 30 mins in presence of [1-14C] L-ornithine by liquid scintillation counter ana...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125005(US8772510, 24)
Affinity DataIC50:  12.4nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124985(US8772510, 4)
Affinity DataIC50:  13.4nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125021(US8772510, 40)
Affinity DataIC50:  13.8nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125001(US8772510, 20)
Affinity DataIC50:  14.5nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125028(US8772510, 47)
Affinity DataIC50:  14.5nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124983(US8772510, 2)
Affinity DataIC50:  16nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125024(US8772510, 43)
Affinity DataIC50:  16.8nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125020(US8772510, 39)
Affinity DataIC50:  18.5nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125009(US8772510, 28)
Affinity DataIC50:  19.3nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124997(US8772510, 16)
Affinity DataIC50:  20.5nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125003(US8772510, 22)
Affinity DataIC50:  21.3nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125007(US8772510, 26)
Affinity DataIC50:  23.8nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125019(US8772510, 38)
Affinity DataIC50:  27.3nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125034(US8772510, 53)
Affinity DataIC50:  31nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125010(US8772510, 29)
Affinity DataIC50:  32.8nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124992(US8772510, 11)
Affinity DataIC50:  34.5nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125011(Roche-Dataset for PDE10A, Compound 67 | US8772510,...)
Affinity DataIC50:  38.5nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125030(Roche-Dataset for PDE10A, Compound 49 | US8772510,...)
Affinity DataIC50:  44.9nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125018(US8772510, 37)
Affinity DataIC50:  45.9nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125042(Roche-Dataset for PDE10A, Compound 68 | US8772510,...)
Affinity DataIC50:  54.2nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125044(Roche-Dataset for PDE10A, Compound 363 | US8772510...)
Affinity DataIC50:  56.9nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124984(US8772510, 3)
Affinity DataIC50:  64nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124993(US8772510, 12)
Affinity DataIC50:  73nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125033(Roche-Dataset for PDE10A, Compound 169 | US8772510...)
Affinity DataIC50:  73.7nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125004(US8772510, 23)
Affinity DataIC50:  77.9nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM237153(US9394304, 15)
Affinity DataIC50:  82nMT: 2°CAssay Description:Harvested cells with 0.025% trypsin/EDTA. Resuspended cells in growth media without selection antibiotics. Measured cell density and diluted to 2.4&t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125014(Roche-Dataset for PDE10A, Compound 61 | US8772510,...)
Affinity DataIC50:  86nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124982(US8772510, 1)
Affinity DataIC50:  86.6nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM124999(US8772510, 18)
Affinity DataIC50:  110nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM237150(US9394304, 12)
Affinity DataIC50:  110nMT: 2°CAssay Description:Harvested cells with 0.025% trypsin/EDTA. Resuspended cells in growth media without selection antibiotics. Measured cell density and diluted to 2.4&t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM237139(US9394304, 1)
Affinity DataIC50:  132nMT: 2°CAssay Description:Harvested cells with 0.025% trypsin/EDTA. Resuspended cells in growth media without selection antibiotics. Measured cell density and diluted to 2.4&t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM125025(US8772510, 44)
Affinity DataIC50:  136nMAssay Description:PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one p...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 168 total ) | Next | Last >>
Jump to: